Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma
Executive Summary
Nandini Piramal, executive director of Piramal Enterprises, discusses how things have shaped the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.
You may also be interested in...
Carlyle Pays Almost $500m For A Fifth Of Piramal Pharma
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Carlyle's 20% Stake Gives Piramal Pharma 'War Chest' For Growth
Private equity group Carlyle has acquired 20% of Piramal’s pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Key Trends In CDMO Space As Dissected By Piramal Pharma Solutions CEO
Piramal Pharma Solutions CEO Vivek Sharma discusses a range of issues shaping the buzzing contract development and manufacturing segment in an interview with Scrip. Heightened consolidation and attractive prospects in the area of antibody drug conjugates, where over 600 clinical trials are being conducted worldwide, are some of the trends to watch out for.